• S2 Episode 1: Are We Ready to Use the Word "Cure" When Talking About Small Cell Lung Cancer Treatment?

  • Feb 16 2023
  • Length: 26 mins
  • Podcast

S2 Episode 1: Are We Ready to Use the Word "Cure" When Talking About Small Cell Lung Cancer Treatment?

Listen for free

View show details

  • Summary

  • Drs Jacob Sands and Jared Weiss discuss subtypes; ongoing clinical trials; durable, ongoing responses to therapy; and the potential for using the word "cure" in the treatment of small cell lung cancer.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Immunotherapy and Lung Cancer Treatment https://www.medscape.com/viewarticle/969534

    Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview

    FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer

    Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext

    Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://ascopubs.org/doi/10.1200/JCO.2006.06.5821

    Study of Trilaciclib and Lurbinectidin https://clinicaltrials.gov/ct2/show/NCT05578326

    PL02.03 Lurbinectedin/Doxorubicin Versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial https://www.jto.org/article/S1556-0864(21)02453-9/fulltext

    Erythropoiesis-Stimulating Agents in Oncology: A Study-Level Meta-Analysis of Survival and Other Safety Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816662

    First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) https://clinicaltrials.gov/ct2/show/NCT05361395

    Bispecific T-Cell Engager (BiTE) Antibodies https://reference.medscape.com/drugs/bispecific-t-cell-engager-bite-antibodies
    Show More Show Less
Show More Show Less
activate_mytile_page_redirect_t1

What listeners say about S2 Episode 1: Are We Ready to Use the Word "Cure" When Talking About Small Cell Lung Cancer Treatment?

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.